Form 1 Sub-study #1

OMB Number: 0925-XXXX

Expiry Date: xx/xx/20xx

Attachment 1:

TECHNOLOGY TRANSFER CENTER

EXTERNAL CUSTOMER SATISFACTION SURVEY (NCIS)

The Technology Transfer Center (TTC) of the National Cancer Institute (NCI) negotiates and manages research collaborations for the NCI Intramural Research Program and nine other Institutes and Centers of the National Institutes of Health (NIH). The NCI Technology Transfer Center does not negotiate licenses, as this activity is relegated solely to the centralized NIH Office of Technology Transfer.

The purpose of the survey is threefold:

- to understand the strategic direction of companies engaging in collaborations and alliances with the NIH;

- to understand the preferred and expected communications channels of TTC’s external customers; and

- to understand how satisfied TTC’s external customers are with its customer services.

Your answers to this survey will provide valuable information on how NIH can improve its services and continue to make significant improvements in public health. The survey is voluntary, and results will only be reported in the aggregate.

Public reporting burden for this collection of information is estimated to vary from 15-20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-xxxx). Do not return the completed form to this address.

Informed Consent Form

Identification of Project	Evaluation of the National Cancer Institute’s Technology Transfer Center
Statement of Age of Subject	I state that I am at least 18 years of age, in good physical health, and wish to participate in research being conducted by the Technology Transfer Center (TTC) of the National Cancer Institute, Rockville, MD 20852.
Purpose	The purpose of this research is to assess the needs of past, current, and potential research collaborators in the biomedical industry in order to improve the technology marketing services that the NCI TTC is able to provide to our internal customers--NIH researchers and administrators.
Procedures	Participants will be asked to access a web-based questionnaire and complete the questionnaire by a specific date. The total time involved, including instructions, will be no more than 20 minutes.
Confidentiality	All information collected in this study will be kept secure to the extent permitted by law. I understand that the data I provide will be grouped with data that others provide for the purpose of reporting and presentation, and that my name will not be used.
Risks	I understand that the risks of my participation are expected to be minimal in nature.
Benefits, Freedom to Withdraw, & Ability to Ask Questions	I understand that this study is not designed to help me personally but that the investigators hope to learn about the industry’s trends in building collaborations; satisfaction with TTC’s services; and preferred communications channels. The survey population will include industry personnel who have utilized TTC’s services. I am free to ask questions or withdraw from participation at any time and without penalty.
Contact Information of Investigators	Name: John D. Hewes, Ph.D. Office: Technology Transfer Center (TTC) of the National Cancer Institute (NCI) Telephone: (301) 496-0477 Email: [email protected]

SECTION 1: RESPONDENT/COMPANY INFORMATION

1. Which of the following best describes your current position in your company?

C-level, Managing Director, Principal, or Founder

Business Development

Scientist, Research Manager/Group Leader

Regulatory Officer

Legal/Patent Counsel

Other (please specify :___________)

2. How is your company best described?

(Please check all that apply.)

For-profit, Pharmaceuticals/Small Molecule Therapeutics

For-profit, Biotechnology/Biological Therapeutics

For-profit, Medical Devices (e.g., implantable devices)

For-profit, Medical Diagnostics (e.g., assays, kits)

For-profit, Laboratory Equipment/Reagents (e.g., instrumentation, biomarkers)

For-profit, Medical Software, Bioinformatics

Other (please specify: )

3. Is your company Private or Public?

Private

Public

4. Where is your company’s parent or headquarters located?

Drop-down menu of countries with United States at the top

5. Approximately how many full-time employees does your company have?

50 or fewer

51 – 500

501 – 5000

More than 5,000

SECTION 2: STRATEGIC DIRECTIONS

6. Does your company develop strategic technology partnerships (research collaborations, licensing, etc.) with outside organizations?

Yes (SKIP TO QUESTION 8)

No

7. Why does your company choose not to develop strategic technology partnerships (research collaborations, licensing, etc.) with outside organizations? (Please check all that apply.)

Regulatory issues

Previous negative experience with a research partner

Dissimilar cultures

Geographic location

Unaware of the possibility

Length of time to negotiate agreements

Other (please specify: ____________)

SKIP TO QUESTION 35

8. When forming a strategic technology relationship with an outside organization, which type of partnership do you typically prefer to start with: (Please check only one.)

Research collaboration

Licensing

Depends on technology

Depends on organization on other side of relationship

Depends on terms of agreement

Other (please specify: ____________)

9. For research and development (not negotiated as in-licenses or contracts), approximately how many research collaborations did you form in the last two years with:

(Please check one in each row.)

Types of research partners, last two years	None	1 – 4	5 – 9	10 or more
Universities
Federal Laboratories (in U.S., also called FFRDCs)
Government Laboratories (non-U.S.)
Non-profits
For-profit, 50 or fewer employees
For-profit, 51 - 500 employees
For-profit, 501 - 5,000 employees
For-profit, more than 5,000 employees
Other (please specify:__________________)

10. For research and development (not negotiated as in-licenses or contracts), approximately how many collaborations do you anticipate forming in the next two years with:

(Please check one in each row.)

Types of research partners, last two years	None	1 – 4	5 – 9	10 or more
Universities
Federal Laboratories (in U.S., also called FFRDCs)
Government Laboratories (non-U.S.)
Non-profits
For-profit, 50 or fewer employees
For-profit, 51 - 500 employees
For-profit, 501 - 5,000 employees
For-profit, more than 5,000 employees
Other (please specify:__________________)

11. How important are the following factors in selecting a research partner?

(Please check one in each row.)

		Not at all Important		A Little Important		Somewhat Important		Very Important		Extremely Important
Talent and knowledge depth in research area
Regulatory expertise
Efficiency (time to complete deal)
Amount of company information that needs to be divulged
Commitment from partner senior management
Commitment from your company’s senior management
Previous experience with partner
Track record of success of potential partner
Similar organizational values
Effectiveness (operational processes)
Terms of intellectual property
Geographic location
Favorable deal terms
Other (please specify: ____________)

12. In general, how does your company find new research partners? (Please check all that apply.)

Financial community recommendation (venture capitalists, investors, etc.)

Personal peer network

Internal scientific staff

Internal or external business, marketing, or competitive intelligence analyst(s)

Notices or alerts sent from subscription services

Marketing/advertising cold call or letter

Other (please specify: ____________)

13. In general, where does your company find new research partners? (Please check all that apply.)

Roadshows

Tradeshows

Scientific and technical conferences

Business partnering conferences

Websites

Peer reviewed scientific literature

Newsletters or trade journals

Social network sites (Twitter, LinkedIn, etc.)

Other (please specify: ____________)

14. For research partnerships developed by your company within the past two years, and that may or may not include licensing, approximately how many were:

(Please check one in each row.)

Types of research partnerships	None	1 – 4	5 – 9	10 or more
Material transfers
U.S. government Collaborative Research and Development Agreements (CRADAs) or Collaboration Agreements
University Collaboration or Sponsored Research Agreements
Exclusively licensed from U.S. Government
Non-exclusively licensed from U.S. Government
Exclusively licensed from university
Non-exclusively licensed from university
Involved a non-U.S. entity, either collaboration or licensing

15. For ALL research partnerships developed by your company within the past two years, that may or may not include licensing, approximately how many were adopted at the following stages:

(Please check one in each row.)

Stage of Research and Development	None	1 – 4	5 – 9	10 or more
Basic Research/Discovery (in vitro)
Pre-clinical (animal studies)
Investigational New Drug completed
Phase I clinical
Phase II clinical
Phase III clinical
Other (please specify:__________________)

16. For ALL research partnerships developed by your company within the past two years, that may or may not include licensing, approximately how many were adopted at the following stages of patent prosecution:

(Please check one in each row.)

Stage of patent prosecution	None	1 – 4	5 – 9	10 or more
US Provisional
PCT Filing (International)
National Filing
Issued patent

17. How important are each of the following to your company in selecting a technology for a research partnership? (Please check one in each row.)

		Not at all Important		A Little Important		Somewhat Important		Very Important		Extremely Important
Stage of research development
Stage of IP Protection
Access to background, pre-existing IP
Availability and terms for IP to be acquired during or after the collaboration

18. Does your company have or plan to have partnerships with off-shore organizations?

Yes

No (SKIP TO QUESTION 22)

19. When considering research and development partnerships with off-shore organizations (not negotiated as in-licenses or contracts), with what kind and how many do you anticipate your company to form in the next two years:

(Please check one in each row.)

Off-Shore Organizations	None	1 – 4	5 – 9	10 or more
Universities
Government or State laboratories or institutes
Contract Research Organizations (CROs)
Other biotech or pharmaceutical companies

20. At what stage of research/development will your company most likely seek off-shore partnerships? (Please check only one.)

Basic Research/Discovery

Pre-clinical

Clinical

Manufacturing

Marketing and Distribution

21. For what reason(s) will your company seek off-shore partnerships? (Please check all that apply.)

Expand market reach

Reduce costs

Access to clinical study populations

Improve research productivity

Access intellectual property

Access to more favorable laws on intellectual property

Access expertise not available internally

Other (please specify: ____________)

SECTION 3: EXPERIENCE WITH NCI TECHNOLOGY TRANSFER CENTER (TTC) SERVICES

22. Patenting and licensing of all NIH technologies are handled centrally by the NIH Office of Technology Transfer (NIH OTT). The NCI TTC has oversight of the NCI technology portfolio and negotiates collaboration agreements, such as CRADAS. Please indicate your level of familiarity with the following prior to receiving this survey.

(Please check one in each row.)

	Not Familiar	A Little Familiarity	Some Familiarity	Very Familiar	Extremely Familiar
NIH OTT
NCI TTC
Cooperative Research and Development Agreements (CRADAs)
NIH Licensing Agreements
NIH Collaboration Agreements
NIH Material Transfer Agreements
NIH Clinical Trial Agreements

23. How did you first learn about the NCI Technology Transfer Center? (Please check only one.)

I received an unsolicited email

Email forwarded to me by a colleague

Internet search (Google, AltaVista, Yahoo, other)

NIH website

NCI website

NIH research staff

Company research staff

Article in magazine or technical or trade publication

Investor

Conference

Other (Please specify: )

24. Should NCI Technology Transfer Center marketing involve an NIH inventor in the process?

Yes

No

25. Has your company developed a research partnership (not in-license) with NIH researchers through the NCI TTC in the past two years?

No

Yes (SKIP TO QUESTION 27)

Don’t know (SKIP TO QUESTION 35)

26. Which factors led you to not partner with NIH researchers? (Please check all that apply.)

Lack of expertise or capabilities in technical area

Regulatory issues

Government march-in rights

NIH purportedly only gives out non-exclusive licenses

No commitment from NIH senior management

No commitment from your senior management

NIH technology transfer office personnel

Previous negative experience with an NIH research partner

Track record of potential NIH research partner

Dissimilar cultures

Operational structure at the NIH

Geographic location

Was unaware of the possibility

NIH overvalues its research/IP

Length of time to negotiate agreements

Terms of the agreement

Not aware of any collaborations with NIH researchers

Other (Please specify: ) SKIP TO QUESTION 35

27. Which factors led you to partner with NIH? (Please select all that apply.)

Access to clinical trials expertise

Access to additional facilities

Access to additional sales and/or marketing capabilities

Access to additional regulatory issues expertise

Access to additional scientific expertise

Track record of NIH researcher or team

Favorable agreement terms

Access to intellectual property

Other (Please specify: )

28. What type of agreement with NIH was most recently completed? (Please check only one.)

Collaboration Agreement

CRADA (Cooperative Research and Development Agreement)

CTA (Clinical Trial Agreement)

MTA (Material Transfer Agreement)

CDA (Confidential Disclosure Agreement)

Exclusive License

Non-exclusive License

Don’t know

29. Were you satisfied with the length of time required to negotiate the agreement?

Yes

No

30. During or immediately following the completion of a collaboration (CRADA, CTA, etc.), were you or your staff given the opportunity to provide specific feedback about the process and your interactions with the technology transfer individual?

YES (SKIP TO QUESTION 32) NO Don’t know

31. Would this provide value to your company?

YES NO Don’t know

32. Please tell us how satisfied you are with each of the following aspects of the NCI TTC technology-transfer staff member’s:

(Please check one in each row.)

	Not satisfied	A little satisfied	Somewhat satisfied	Very satisfied	Extremely satisfied
Responsiveness during a negotiation.
Knowledge of the technology transfer process.
Understanding of your business priorities.
The information provided to you.
Level of motivation and engagement toward teaming.
Communication frequency with your company during a negotiation.

33. Please provide additional comments and/or recommendations regarding TTC’s customer services.

34. How do you or your staff locate NIH research partners for potential collaborations or partnerships? (Please check all that apply.)

Roadshows

Financial community recommendation (venture capitalists, investors, etc.)

Industry analyst reports

Tradeshows

Scientific and technical conferences

Partnering conferences

Personal networks

Internal company analyst(s)

Established relationships with NIH researcher(s)

Notices sent from the NIH email, RSS, or Listserv

NIH/NCI Websites

NIH marketing/advertising cold calls or letters to R&D

Don’t know

35. Would you like to receive information from the NCI Technology Transfer Center on developing research collaborations with the NIH?

Yes

No (SKIP TO 38)

36. What types of information would you like to receive from the NCI Technology Transfer Center? (Please check all that apply.)

Technology transfer/intellectual property policy updates

Recent licenses and collaborations negotiated at NCI

New technology collaboration opportunities from NCI or other NIH Institutes

New technology licensing opportunities from NIH Institutes

Information only about technologies that complement a profile you create for NIH

Information about NIH scientific events and meetings

37. What is your preferred method of receiving NCI Technology Transfer Center information? (Please check only one.)

Email

RSS feed

Hardcopy newsletter

Facebook, LinkedIn, or other social web application

“What’s New” site on the Technology Transfer Center website

38. Are there services not currently offered by the NCI Technology Transfer Center that would be useful to meet the technology transfer needs of your company?

If you would like to be put on the NIH Technology Transfer Center mailing list, please go to the following website: http://ttc.nci.nih.gov/

THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE

-----------------------------------END OF INSTRUMENT-------------------------------

13